ASTRA’S TURNAROUND IS A CASE STUDY FOR BIG PHARMAS (BUY; 37% UPSIDE)
21/09/23 -" In an investing world that increasingly craves instant gratification (and often falls prey), it is worth looking at AstraZeneca’s (BUY; UK) journey over the last decade. Its phoenix-like rise from ..."
Pages
73
Language
English
Published on
21/09/23
You may also be interested by these reports :
10/05/25
Genmab reported mixed Q1 results. Strong sales growth, driven by key offerings, resulted in solid profitability. Although our model is under review, ...
09/05/25
Novonesis delivered a strong start to FY25, with 11% organic revenue growth and a 310bps expansion in adjusted EBITDA margin to 38.3%, both ahead of ...
07/05/25
Q1 profits exceeded the street’s expectations. Nonetheless, 2025 guidance was downgraded owing to competition from compounded drugs, which, however, ...
06/05/25
1:10 share split adjustments – Downgrade to Add (prev.: Buy)